Therapnea

**Therapnea™ – A Game Changer in the Vastly Underserved Multi-Billion-Dollar Market for treating Obstructive Sleep Apnea (OSA) and Snoring.** **The “Silent Killer”** Over 900 million people worldwide suffer from **Obstructive Sleep Apnea (OSA)** — of which 8**0% remain undiagnosed and untreated.** That’s twice as many as diabetes patients, yet **OSA** remains largely ignored despite its devastating consequences. **OSA** is linked to serious comorbidities such as: **Cardiovascular disease         Chronic Fatigue – Micro Sleep            Hypertension       Depression Stroke          Sexual Dysfunction, Libido Loss Diabetes       Premature Death** Untreated **OSA** increases mortality **by 39%** earning it the name **“The Silent Killer”** **Market Opportunity** **Vast Untapped Demand** The global **OSA** therapy market is worth **billions** yet it remains **critically underserved**. The **golden standard therapy** is **CPAP** (Continues Positive Airway Pressure) using as air pump and facial mask. **Critical Gap in Care** Among those diagnosed moderate to severe, **up to 50%** are unable to adhere to **CPAP** therapy – leaving over **40 million** diagnosed patients **without effective treatment** today. **Proven Economic Value** Treating **OSA** significantly reduces long-term healthcare costs by preventing chronic disease progression, lowering hospitalization rates and cardiovascular risks. Payers and health systems have every incentive to achieve higher therapy adherence. **Additional Market: Snoring** **Therapnea™** also addresses the 1**00-200 million chronic snorers** seeking alternatives – unlocking a **second multi-billion-Dollar market.**  **Therapnea Labs offers hope.** We bring a **real solution** — one that is effective, tolerable. **The Advantages of Therapnea™ Technology and Devices**  **1\. Breakthrough Technology for Moderate to Severe OSA** Our advanced, proprietary solution addresses the ~50% of the market that cannot tolerate **CPAP** and currently has no alternative solution. With **Therapnea™**, tens of millions of people can finally experience meaningful relief. The system most probably be **Class II**.  **2\. Innovative Solution for Heavy Snoring** Snoring has long lacked an effective remedy. Our unique technology offers real relief to millions worldwide, filling a major gap in the sleep-health market. Most likely be **OTC**.  **3\. Smart Devices with Rich Data Collection** Our devices monitor multiple parameters throughout the sleep and securely transmit this data to both the patient’s physician and our platform. This creates an unparalleled database on sleep disorders, supporting personalized care and ongoing innovation.  **4\. Robust Global IP Portfolio** Therapnea Labs holds strong, granted patents across key markets, including the USA, Europe, China, Hong Kong, Japan, India, Russia, Israel and more — providing a formidable competitive moat.  **5. Clinically Proven Tolerability** Our proof-of-concept clinical study confirmed excellent patient acceptance. No gag reflex issues were observed, and the active device component — the stent — was well tolerated by all participants. A questionnaire done in a sleep lab in Israel showed 72% prefer traying **Therapnea™** rather than **CPAP**  **6\. Massive Market Potential & ROI** With **OSA** and **Snoring** representing multi-billion-dollar markets, **Therapnea™** is positioned for exceptional growth and the potential to become the next health-tech unicorn. Major sales may be done on **B2B** basis.  **7. World-Class Team** Our **“AAA”** team combines deep expertise, proven experience, and unmatched motivation — the driving force behind our success.